STAAR Surgical Company (NASDAQ: STAA) witnessed a substantial market surge in its latest trading session, climbing 46.13% to close at $27.02, following the announcement of a definitive merger agreement.
Top 5 Tech Stocks to Buy in 2024
Don't let the chaos of rising interest rates, potential recession, tighter credit issues, higher oil prices, and incessant geopolitical issues chase you from the markets. Instead, just wait it out. With too much fear in the market, go bargain hunting with tech stocks. We have complied a report with the five of the best ways to profit within this industry.
"Top 5 AI Stocks to Buy in 2024."
Click here to sign up for our free report & newsletter, plus bonus offer "Elon Musk just Tiggered a BOOM in These Stocks"
Sponsored
STAAR to Merge in a Multi-Billion Acquisition Deal
In a deal valued at about $1.5 billion, STAAR Surgical will be purchased by Alcon (SIX/NYSE: ALC), a world leader in eye care. As per the deal, Alcon will pay $28 per share in cash for all outstanding STAAR common shares.
That is a 59% premium over the 90-day Volume Weighted Average Price (VWAP) of STAAR and a 51% premium over the closing price on August 4, 2025.
Strengthening Surgical Vision Correction Portfolio
The acquisition includes STAAR’s EVO family of implantable collamer lenses (EVO ICL), designed to correct moderate to high myopia, with or without astigmatism. For individuals who are not good candidates for other refractive treatments like LASIK, these less invasive, reversible lenses offer a surgical option.
By incorporating EVO ICL technology, Alcon hopes to broaden its product line to include anything from surgical options to contact lenses for the treatment of myopia.
Trends in Global Myopia Fuel Strategic Expansion
The incidence of myopia is rising quickly; estimates indicate that by 2050, almost 50% of people worldwide will have the condition, including 500 million people with extreme myopia.
A sizable chunk of this market is served by the EVO ICL product line, which is positioned between the iris and natural crystalline lens without removing corneal tissue. Alcon hopes to address rising demand and demonstrate its dedication to cutting-edge eye care solutions by implementing STAAR’s cutting-edge technology.
Getting Past Market Obstacles and Growing Adoption
Over the last two years, STAAR Surgical has seen varying demand in important markets, especially China, which has affected its trajectory of independent growth. It is anticipated that the adoption of EVO ICL technology would speed dramatically due to Alcon’s larger scale, global presence, and resources, extending its reach among surgeons and patients globally.
Since Alcon intends to finance the acquisition using a combination of short- and long-term credit facilities, the agreement is not subject to financing requirements. This calculated action strengthens Alcon’s position as the industry leader in ophthalmics and demonstrates its commitment to providing comprehensive vision correction solutions.
